SAGE-718 Chemical Structure oral NMDAR positive allosteric modulator - Sage Therapeutics, Inc., Cambridge, MA

oral NMDAR positive allosteric modulator

Ph. II candidate in neurology

from previously disclosed PAM and opt

J. Med. Chem.

Sage Therapeutics, Inc., Cambridge, MA

Context. SAGE-718 (Sage Therapeutics) is an oral N-methyl-d-aspartate receptor (NMDAR) Positive Allosteric Modulator (PAM) being developed for cognitive impairment in Huntington’s disease. Aberrant NMDAR signaling has been implicated in…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.